![MRD-Guided Cessation of Treatment in Patients Receiving Venetoclax/Ibrutinib for Relapsed or Refractory CLL - The ASCO Post MRD-Guided Cessation of Treatment in Patients Receiving Venetoclax/Ibrutinib for Relapsed or Refractory CLL - The ASCO Post](https://ascopost.com/media/14020377/12-kater.jpeg?anchor=center&mode=crop&width=400&height=300&rnd=133026446730000000)
MRD-Guided Cessation of Treatment in Patients Receiving Venetoclax/Ibrutinib for Relapsed or Refractory CLL - The ASCO Post
![MURANO Trial: Venetoclax Plus Rituximab Achieves Durable Progression-Free Survival in Resistant CLL - The ASCO Post MURANO Trial: Venetoclax Plus Rituximab Achieves Durable Progression-Free Survival in Resistant CLL - The ASCO Post](https://ascopost.com/media/14016077/54-kater.jpg?anchor=center&mode=crop&width=400&height=300&rnd=132579761590000000)
MURANO Trial: Venetoclax Plus Rituximab Achieves Durable Progression-Free Survival in Resistant CLL - The ASCO Post
![Arnon Kater on CLL Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab - The ASCO Post Arnon Kater on CLL Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab - The ASCO Post](https://cf-images.us-east-1.prod.boltdns.net/v1/static/5813221795001/dccfcbdf-2e6e-43fa-b1e1-af9463337658/77f08c8e-a6d9-4d41-9033-8ac48ebee307/1280x720/match/image.jpg)
Arnon Kater on CLL Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab - The ASCO Post
![Arnon Kater on CLL Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab - The ASCO Post Arnon Kater on CLL Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab - The ASCO Post](https://cf-images.us-east-1.prod.boltdns.net/v1/static/5813221795001/97dc97d2-8f40-4b28-a278-692103ce2e6d/1c799495-306c-46b2-bd94-05ebd3769e9d/1280x720/match/image.jpg)